
Multidisciplinary Frameworks for Individualized ICI-Based Treatment Regimens in the Advanced Melanoma Setting
Released On
August 29, 2025
Expires On
August 29, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Dermatology, Oncology, Pharmacy, and Surgery
Topic(s)
Multiple Myeloma, Oncology
This educational activity is presented in collaboration with Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Bristol Myers Squibb.
Credit Available
- Physicians — maximum of 1.00 AMA PRA Category 1 Credits™
- Nurses — maximum of 1.0 nursing contact hour(s)
- Pharmacists — maximum of 1.0 contact hour(s)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is intended for oncologists and the multidisciplinary care team who manage patients with melanoma.
Program Overview
The treatment landscape for advanced melanoma has dramatically shifted over the past decade thanks to the introduction of innovative therapies such as immunotherapies that have not only improved survival rates but also significantly enhanced patients’ quality of life.
Yet despite the availability of evidence-based guidelines regarding the use of immune checkpoint inhibitors (ICIs) in melanoma, their use remains suboptimal in clinical practice. Clinicians may be unfamiliar with the evidence-based changes in treatment approaches that have accompanied new research and approvals over the past few years. Balancing indications and recommendations with safety considerations for these therapies, particularly when used in combination, may also prove challenging.
To help clinicians enhance their ICI-based treatment regimens in the advanced melanoma setting, this interactive practice guide interweaves education and practical guidance for easy integration of the latest evidence and treatment strategies within daily clinical processes and workflows.
Learning Objectives
Upon completion of this activity, learners will be able to:
- Interpret and apply clinical trial and real-world evidence in the advanced melanoma treatment setting
- Integrate ICI-based monotherapies and combination therapies into evidence-based treatment plans for appropriate patients with advanced melanoma
- Implement multidisciplinary collaboration frameworks to identify and engage patients, personalize treatment selection, and manage immune-related adverse events (irAEs) in patients with advanced melanoma
Agenda
Content topics
- Incidence and Burden of Advanced Melanoma
- Treatment Landscape
- Considerations for Treatment Selection
- ICIs for Adjuvant Therapy
- Monitoring and Managing Immune-Related Adverse Events (irAEs)
Faculty

April K.S. Salama, MD
Associate Professor of Medicine
Vice Chief for Culture, Engagement and Community
Division of Medical Oncology
Director, Melanoma Program
Medical Director, Clinical Trials Office
Duke Cancer Institute
Durham, NC
Accreditation Statement


In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Credit Designation
Rush University Medical Center designates this Enduring Material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Rush University Medical Center designates this Enduring Material for a maximum of 1.0 nursing contact hour(s)
Rush University Medical Center designates this application-based activity for a maximum of 1.0 contact hour(s) for pharmacists. ACPE Universal Activity Number: JA0000275-0000-25-215-H01-P

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
Disclosures of Conflicts of Interest
It is the policy of the Interprofessional Continuing Education office at Rush to ensure that its CE activities are independent, free of commercial bias. Therefore, we manage all financial relationships associated with accredited continuing education activities. Rush asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. There is no minimum threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of relationships to education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the planning, implementation, or evaluation of the continuing education activity. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.
Individuals in control of content for this activity have the following relevant financial relationships with ineligible companies to disclose and all financial relationships have been mitigated.
The following financial relationships have been provided:
April K.S. Salama, MD
Scientific Advisor: Bristol Myers Squibb, Pfizer, Regeneron
Sources of Funding for Research (paid to institution): Bristol Myers Squibb, Ideaya, Immunocore, Merck, Olatec Therapeutics, Regeneron, Riplimune, Seagen
Staff and Reviewer Disclosures:
Rush University Medical Center and the Office of Interprofessional Continuing Education staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Karen Catino at [email protected]
Course Viewing Requirements:
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclaimer
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of any publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: None
Contact Information
For questions, contact Karen Catino at [email protected].